Updated Jul 13, 9:31 PM · 60 sources analyzed
Key Takeaways
Levomecor terminated both Phase 3 REL-1017 MDD trials simultaneously, ending esmethadone's path to market as an adjunctive antidepressant.
United Therapeutics' ralinepag Phase 3 PAH trial also terminated, narrowing the company's pipeline beyond its Tyvaso franchise anchor.
Syndax's revumenib solid tumor expansion trial was terminated, confining the approved menin inhibitor to its hematology niche for now.
📉 Loser
Levomecor Inc. — simultaneous termination of both Phase 3 trials ends REL-1017's development program for major depressive disorder
🔭 Watch Next
Watch for Sanofi to disclose rilzabrutinib Phase 2 atopic dermatitis data at a dermatology or immunology conference in H2 2026, the most commercially significant pending readout visible in today's registry updates.
Levomecor Terminates Both Phase 3 REL-1017 MDD Trials
Levomecor Inc. has terminated two separate Phase 3 randomized, placebo-controlled trials of REL-1017 (esmethadone) as adjunctive treatment for major depressive disorder, according to ClinicalTrials.gov registry updates. Both studies — NCT06011577 and NCT04855747 — were terminated, ending what had been a closely watched bet on an NMDA receptor channel blocker as a fast-acting antidepressant. The back-to-back Phase 3 terminations effectively close the door on REL-1017 as a near-term MDD entrant, leaving Axsome, Relmada's former investors, and the broader fast-acting antidepressant field to absorb the signal that NMDA-targeted mechanisms remain difficult to advance at scale.
ClinicalTrials.gov ↗Levomecor Inc.
REL-1017 (esmethadone) in Major Depressive Disorder
Both Phase 3 randomized, double-blind, placebo-controlled trials (NCT06011577 and NCT04855747) are now listed as Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in conjunction with these registry updates; the reasons for termination have not been publicly disclosed.
Why it matters
Two simultaneous Phase 3 terminations without a disclosed efficacy rationale is the worst kind of signal — it suggests the program ran into a problem serious enough to stop rather than complete. For investors watching the fast-acting antidepressant space, this narrows the competitive set further and may benefit assets already on market or in late-stage development with cleaner data packages.
What to watch
Watch for any public disclosure from Levomecor on the reason for termination — whether safety, futility, or commercial — which will determine how much read-across applies to other NMDA-targeting depression programs in development.
United Therapeutics
Ralinepag in Pulmonary Arterial Hypertension (WHO Group 1)
The ADVANCE CAPACITY Phase 3 trial (NCT04084678), designed to evaluate ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) measured by cardiopulmonary exercise testing, is now listed as Terminated on ClinicalTrials.gov. No efficacy data accompany the registry status change.
Why it matters
United Therapeutics already has Tyvaso DPI as a commercial anchor, so ralinepag's loss is a pipeline setback rather than an existential one — but it narrows the company's long-term differentiation story and may prompt investors to reassess the pipeline's depth beyond Tyvaso franchise lifecycle extensions.
What to watch
Watch for United Therapeutics' next pipeline update call to hear management's explanation for the termination and whether any redirected resources are flowing toward other PAH or rare disease programs.
Syndax Pharmaceuticals
Revumenib in Colorectal Cancer and Other Solid Tumors
A Phase 1/2 study evaluating revumenib — a menin inhibitor (a drug that blocks a protein involved in leukemia and some solid tumor growth) — in patients with colorectal cancer and other solid tumors (NCT05731947) is now listed as Terminated on ClinicalTrials.gov. No safety or anti-tumor activity data have been disclosed with the registry update.
Why it matters
Syndax's core value remains in the hematology indication where revumenib is approved, but the solid tumor termination forecloses a potentially large label expansion opportunity and removes a narrative that had supported a broader addressable market thesis for the asset.
What to watch
Watch for Syndax's next pipeline and commercial update to hear whether additional menin inhibitor expansion indications remain in active development or whether the company is narrowing focus to hematology.
Sanofi
Rilzabrutinib in Atopic Dermatitis (moderate-to-severe)
A Phase 2 double-blind, placebo-controlled proof-of-concept study of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis (NCT05018806) is now listed as Completed on ClinicalTrials.gov. Full efficacy and safety data have not been released in conjunction with this registry update.
Why it matters
Sanofi's dermatology franchise is already anchored by dupilumab, so rilzabrutinib in atopic dermatitis is a strategic hedge rather than a core asset — the data will matter most for understanding how BTK inhibition positions across Sanofi's broader immunology pipeline including ITP and pemphigus.
What to watch
Watch for Sanofi to present rilzabrutinib atopic dermatitis Phase 2 data at a dermatology or immunology medical meeting in the second half of 2026.
Both Phase 3 randomized, double-blind, placebo-controlled trials (NCT06011577 and NCT04855747) are now listed as Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in conjunction with these registry updates; the reasons for termination have not been publicly disclosed.
Why it matters
Dual Phase 3 terminations effectively end REL-1017's path to market, removing a once-credible NMDA antagonist competitor from the fast-acting antidepressant field and reinforcing the difficulty of replicating ketamine-like mechanisms in a scalable, approvable drug.
Analysis
Two simultaneous Phase 3 terminations without a disclosed efficacy rationale is the worst kind of signal — it suggests the program ran into a problem serious enough to stop rather than complete. For investors watching the fast-acting antidepressant space, this narrows the competitive set further and may benefit assets already on market or in late-stage development with cleaner data packages.
What to watch
Watch for any public disclosure from Levomecor on the reason for termination — whether safety, futility, or commercial — which will determine how much read-across applies to other NMDA-targeting depression programs in development.
The ADVANCE CAPACITY Phase 3 trial (NCT04084678), designed to evaluate ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) measured by cardiopulmonary exercise testing, is now listed as Terminated on ClinicalTrials.gov. No efficacy data accompany the registry status change.
Why it matters
The termination of a Phase 3 PAH (pulmonary arterial hypertension, a serious lung condition that raises blood pressure in the pulmonary arteries) trial for ralinepag removes a pipeline asset from United Therapeutics' next-generation prostacyclin portfolio and cedes ground to competitors in an increasingly crowded PAH space.
Analysis
United Therapeutics already has Tyvaso DPI as a commercial anchor, so ralinepag's loss is a pipeline setback rather than an existential one — but it narrows the company's long-term differentiation story and may prompt investors to reassess the pipeline's depth beyond Tyvaso franchise lifecycle extensions.
What to watch
Watch for United Therapeutics' next pipeline update call to hear management's explanation for the termination and whether any redirected resources are flowing toward other PAH or rare disease programs.
A Phase 2 double-blind, placebo-controlled proof-of-concept study of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis (NCT05018806) is now listed as Completed on ClinicalTrials.gov. Full efficacy and safety data have not been released in conjunction with this registry update.
Why it matters
Rilzabrutinib's BTK inhibitor (a drug that blocks a protein involved in immune cell signaling) mechanism is being evaluated across multiple immune conditions; the atopic dermatitis readout will test whether oral BTK inhibition can compete with established biologics like dupilumab in a crowded field.
Analysis
Sanofi's dermatology franchise is already anchored by dupilumab, so rilzabrutinib in atopic dermatitis is a strategic hedge rather than a core asset — the data will matter most for understanding how BTK inhibition positions across Sanofi's broader immunology pipeline including ITP and pemphigus.
What to watch
Watch for Sanofi to present rilzabrutinib atopic dermatitis Phase 2 data at a dermatology or immunology medical meeting in the second half of 2026.
A Phase 2 study evaluating the safety, tolerability, pharmacokinetics (how the body processes the drug), and pharmacodynamic effects (what the drug does to the body) of AZD2389 versus placebo in participants with liver fibrosis and compensated cirrhosis (NCT06750276) is now listed as Completed on ClinicalTrials.gov. No efficacy or biomarker data have been disclosed alongside this status update.
Why it matters
Liver fibrosis is a large unmet-need space with no approved antifibrotic therapies beyond treating the underlying cause, making any credible Phase 2 signal from a novel mechanism strategically significant for AstraZeneca's expanding cardiovascular-renal-metabolic portfolio.
Analysis
AZD2389's mechanism has not been publicly characterized in detail, which makes the Phase 2 completion a data-pending story rather than a conclusion — investors will need to see the biomarker and safety readout to assess whether this asset has the pharmacological profile to justify Phase 3 investment in a field where several programs have failed.
What to watch
Watch for AstraZeneca to disclose AZD2389 Phase 2 data at a hepatology conference such as AASLD or EASL in the coming months.
A Phase 1/2 study evaluating revumenib — a menin inhibitor (a drug that blocks a protein involved in leukemia and some solid tumor growth) — in patients with colorectal cancer and other solid tumors (NCT05731947) is now listed as Terminated on ClinicalTrials.gov. No safety or anti-tumor activity data have been disclosed with the registry update.
Why it matters
Revumenib is already approved for relapsed/refractory acute leukemia with certain genetic mutations, so the solid tumor program termination narrows the expansion story and signals that the menin inhibitor mechanism may not translate cleanly beyond its hematology niche.
Analysis
Syndax's core value remains in the hematology indication where revumenib is approved, but the solid tumor termination forecloses a potentially large label expansion opportunity and removes a narrative that had supported a broader addressable market thesis for the asset.
What to watch
Watch for Syndax's next pipeline and commercial update to hear whether additional menin inhibitor expansion indications remain in active development or whether the company is narrowing focus to hematology.
Intranasal Insulin for PTSD Completes Phase 2 at VA Connecticut
A Phase 2 study evaluating intranasal insulin for reducing PTSD (post-traumatic stress disorder) symptoms in veterans has been marked Completed on ClinicalTrials.gov, though no efficacy or safety data have been released publicly.
Why it matters
Intranasal insulin represents a novel, non-opioid, non-benzodiazepine approach to PTSD — a condition with a large underserved veteran population and limited approved pharmacotherapies — making any signal of efficacy potentially significant for CNS drug developers.
Analysis
PTSD remains one of the largest underserved CNS indications, and the VA system's involvement in this study adds credibility to the patient population relevance. The completion of the trial without public data is a placeholder event; the mechanistic rationale for insulin's role in fear memory consolidation is scientifically legitimate but requires clinical proof before attracting serious commercial interest.
What to watch
Watch for VA Connecticut or collaborating academic authors to publish Phase 2 results in a peer-reviewed journal or present at a psychiatry conference in the next 12 months.
Stem Cell Gene Therapy for RAG1-Deficient SCID Trial Suspended
A Phase 1/2 multicentre stem cell gene therapy trial for RAG1-deficient SCID (severe combined immunodeficiency, a rare and fatal immune disorder in infants) run by Genewity Holding B.V. has been placed in Suspended status on ClinicalTrials.gov.
Why it matters
Gene therapy for primary immunodeficiencies is a competitive but technically demanding space; a suspension — which differs from termination in that enrollment is paused rather than ended — often signals a regulatory hold, manufacturing issue, or safety review that could affect the broader field's regulatory environment.
Analysis
The distinction between suspension and termination matters here: a suspension preserves the option to restart, suggesting the underlying science and program may not be permanently foreclosed. Developers and investors in rare pediatric gene therapy should monitor whether this suspension is safety-driven, which would carry read-across risk to analogous programs.
What to watch
Watch for Genewity or the trial's coordinating center to disclose the reason for suspension and whether a regulatory hold has been issued by a European or U.S. authority, which would be the key read-across signal for the broader SCID gene therapy field.
Etigilimab Plus Nivolumab Trial Active in Platinum-Resistant Ovarian Cancer
A Phase 2 single-arm study of etigilimab (OMP-313M32, an anti-TIGIT antibody) combined with nivolumab (a PD-1 checkpoint inhibitor) in platinum-resistant clear cell ovarian, fallopian tube, and primary peritoneal cancers is active and not recruiting at MD Anderson Cancer Center.
Why it matters
Platinum-resistant ovarian cancer has extremely limited treatment options and historically poor responses to checkpoint inhibitors alone; if anti-TIGIT plus anti-PD-1 combination shows durable responses in this setting, it would validate the TIGIT pathway as a meaningful target in gynecologic cancers beyond the existing PD-L1 literature.
Analysis
The TIGIT field has had a difficult run with high-profile Phase 3 failures from Roche and other large sponsors, making this MD Anderson-led Phase 2 a scientific signal-finding exercise rather than a near-term commercial catalyst. Any positive ORR (the share of patients whose tumors shrank) data from this trial would reopen serious questions about patient selection and biomarker-driven TIGIT strategies.
What to watch
Watch for MD Anderson to present etigilimab plus nivolumab efficacy and safety data from this study at ASCO, SGO, or ESMO in 2026–2027, with particular attention to whether clear cell histology shows differential benefit.
Erasca, Inc.
Erasca, Inc. filed an 8-K under Item 8.01 with the SEC on July 13, 2026; the specific disclosure content has not been described in the filing summary.
Why it matters
Item 8.01 is a catch-all SEC disclosure category, and without knowing the substance of Erasca's filing it is not possible to assess clinical, regulatory, or commercial significance — the filing is noted here solely because Erasca is a watchlist company.
Analysis
Erasca's most closely watched asset is naporafenib in RAS/MAPK-driven cancers; any material clinical, regulatory, or partnership development would be disclosed via a more specific 8-K item. Until the content of this Item 8.01 filing is clarified, it should not drive model updates.
What to watch
Watch for the full text of Erasca's 8-K Item 8.01 filing to determine whether it contains a clinical data update, regulatory action, or partnership event relevant to the naporafenib program.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.